{"id":"NCT02180217","sponsor":"Novartis Pharmaceuticals","briefTitle":"Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease","officialTitle":"Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-10-06","primaryCompletion":"2018-02-21","completion":"2019-12-04","firstPosted":"2014-07-02","resultsPosted":"2020-06-16","lastUpdate":"2021-01-06"},"enrollment":137,"design":{"allocation":"RANDOMIZED","model":"SEQUENTIAL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Cushings Disease"],"interventions":[{"type":"DRUG","name":"osilodrostat","otherNames":["LCI699"]},{"type":"DRUG","name":"LCI699 matching placebo","otherNames":[]}],"arms":[{"label":"osilodrostat (LCI699)","type":"EXPERIMENTAL"},{"label":"LCI699 Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study aimed to confirm long-term efficacy and safety of LCI699 for the treatment of patients with Cushing's disease. It was a pivotal trial which supported the registration of LCI699 for the treatment of patients with Cushing's disease in the US and the EU.\n\nThis is a phase lll, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period which evaluated the safety and efficacy of LCI699 for the treatment of patients with Cushing's disease.","primaryOutcome":{"measure":"Percentage of Primary Efficacy Responder at Week 34 by Randomized Treatment and Strata","timeFrame":"Week 34 (8 weeks)","effectByArm":[{"arm":"Osilodrostat (LCI699)","deltaMin":86.1,"sd":null},{"arm":"LCI699 Placebo","deltaMin":29.4,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":60,"countries":["United States","Argentina","Austria","Bulgaria","Canada","China","Colombia","France","Germany","India","Italy","Japan","Netherlands","Russia","South Korea","Spain","Thailand","Turkey (TÃ¼rkiye)","United Kingdom"]},"refs":{"pmids":["39610378","38696122","37680892","33074401","32730798"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":36},"commonTop":["Nausea","Headache","Fatigue","Adrenal insufficiency","Vomiting"]}}